Listed by the USPTO as WHITE, DAWANNA SHAR-DAY
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 62% of resolved cases
WHITE, DAWANNA SHAR-DAY is assigned to Tech Center 1600 and Art Unit 1627. The record covers 125 resolved cases, with an allowance rate of 62.4% and a median of 1262 days to allowance. The 24.3% interview lift is positive, suggesting that interviews may help advance applications where the parties can identify a concrete path through the outstanding issues.
The listed companies are Vanda Pharmaceuticals Inc., Hoffmann-La Roche Inc., and Novartis AG. The listed firms are HOFFMAN WARNICK LLC, Jones Day, and McCarter & English, LLP. Practitioners should use interviews to clarify the examiner's technical position, then present focused amendments with matching support in the specification. The 1262-day median favors early attention to prosecution efficiency and preservation of commercially relevant claim scope.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18951962 | GPR88-RECEPTOR-AGONIST | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18837245 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Non-Final OA | BIOGEN MA INC. |
| 18034965 | METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.4% of resolved applications examined by Dawanna Shar-Day White were allowed (125 resolved cases), compared with 35.1% across Art Unit 1627 over the last five years.
This examiner's interview lift is +24.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dawanna Shar-Day White took 1,262 days on average from filing to allowance.
Dawanna Shar-Day White examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
